In the final analysis of the randomized, phase 3 RATIONALE-312 trial (data cutoff: April 19, 2023), patients with extensive-stage SCLC (ES-SCLC) who received first-line tislelizumab plus chemotherapy experienced significant improvements in overall survival (OS; HR = 0.75 [95% CI: 0.61–0.93]; one-sided p = 0.004) and tolerable toxicity compared with placebo plus chemotherapy. We report long-term follow-up (data cutoff: December 29, 2023) data.
In the final analysis of the randomized, phase 3 RATIONALE-312 trial (data cutoff: April 19, 2023), patients with extensive-stage SCLC (ES-SCLC) who received first-line tislelizumab plus chemotherapy experienced significant improvements in overall survival (OS; HR = 0.75 [95% CI: 0.61–0.93]; one-sided p = 0.004) and tolerable toxicity compared with placebo plus chemotherapy. We report long-term follow-up (data cutoff: December 29, 2023) data.